SkinBioTherapeutics (LON:SBTX) Shares Up 9.9% – Time to Buy?

SkinBioTherapeutics plc (LON:SBTX)’s share price was up 9.9% on Monday . The company traded as high as GBX 10.13 and last traded at GBX 10.11. Approximately 995,038 shares changed hands during trading, a decline of 79% from the average daily volume of 4,648,261 shares. The stock had previously closed at GBX 9.20.

SkinBioTherapeutics Stock Up 9.9%

The company has a quick ratio of 10.01, a current ratio of 4.84 and a debt-to-equity ratio of 10.55. The stock has a market capitalization of £26.20 million, a P/E ratio of -32.61 and a beta of 0.47. The company has a fifty day moving average price of GBX 12.75 and a 200-day moving average price of GBX 14.72.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.